Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences:
- Guggenheim Healthcare Talks/Oncology Conference: Wednesday, February 8 at 11:20-11:45 a.m. ET
- SVB Securities Global Biopharma Conference: Tuesday, February 14 at 3:40-4:10 p.m. ET
- Citi's 2023 Oncology Leadership Summit: Thursday, February 23 at 10:00-11:00 a.m. ET
The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and Twitter.
Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 202518.4.2024 08:00:00 CEST | Press release
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group N.V. launches new convertible bond offering and simultaneously invites holders of its outstanding €125 million 3.00% convertible bonds due 2025 to offer their convertible bonds for purchase for cash Leiden, the Netherlands, 18th April, 2024: Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) launches today the issue of approximately €100 million senior unsecured convertible bonds due 2029 (the “New Bonds”) convertible into new and/or existing ordinary shares in the capital of the Company (the “Shares”) and concurrently invites current holders of its outstanding €125 million 3.00% convertible bonds due 2025 to submit offers to sell for cash. The New Bonds are expected to be issued on 25th April 2024 (the “Issue Date”) and to carry a coupon of 4.50% per a
AS Tallink Grupp will hold an Investor Webinar to introduce the results of the first quarter of 202418.4.2024 08:00:00 CEST | Press release
All shareholders and other stakeholders are invited to join the webinar, scheduled to take place on 25April 2024 at 12:00 (EET).The webinar will be held in English. The financial results will be presented by the Chairman of the Management Board Paavo Nõgene and the members of the Management Board Margus Schults and Harri Hanschmidt. We kindly ask participants to provide their questions before the webinar, latest by 11:00 am on 25April, by e-mail to: investor@tallink.ee. Due to time constraint, preference will be given to questions submitted in writing before the webinar. How to join the webinar? The webinar will be hosted on the Microsoft Teams platform. Please note that to participate, no prior registration is required, and no reminder of the webinar will be sent. To participate, please join the webinar on25April 2024 at 12:00 (EET) via the following link. As there is no prior registration needed and no reminder of the webinar will be sent, we recommend that allinterested parties mark
Vallourec progresses its holistic balance sheet refinancing with successful pricing of its 2032 Senior Notes offering18.4.2024 07:30:00 CEST | Press release
Vallourec progresses its holistic balance sheet refinancing with successful pricing of its 2032 Senior Notes offering Meudon (France), April 18, 2024 – Vallourec S.A., (the “Company” and, together with its subsidiaries, the “Group”), a world leader in premium tubular solutions, announces today that it has successfully priced an offering of Senior Notes due 2032 (the “Notes”) in an aggregate principal amount of $820 million, which will be issued at par and will bear interest at a rate of 7.500% per annum. The offering of the Notes is expected to close on April 23, 2024, subject to customary closing conditions. Upon completion, the proceeds from the offering of the Notes will be used, together with cash on hand, to (i) fund the redemption of the Company’s €1,023.4 million in aggregate principal amount of 8.5% senior notes due 2026 (the “Existing Notes”) and pay accrued and unpaid interest thereon, (ii) repay approximately €68 million outstanding under the Company’s existing state-guarant
Aspocomp’s Interim Report January 1 – March 31, 2024: Net sales and operating result decreased from the comparison period18.4.2024 07:00:00 CEST | Press release
Aspocomp Group Plc, Interim Report, April 18, 2024, at 8:00 a.m. (Finnish time) FIRST QUARTER 2024 HIGHLIGHTS Net sales EUR 6.2 (8.9) million, decrease of 30%Operating result EUR -1.6 (0.3) million, -25.9% (3.8%) of net salesEarnings per share EUR -0.24 (0.04)Operative cash flow EUR -2.0 (1.6) millionOrders received EUR 7.5 (13.7) million, decrease of 45%Order book at the end of the review period EUR 11.8 (19.1) million, decrease of 38%Equity ratio 64.5% (72.9%) OUTLOOK FOR 2024 Inflation and interest rates, weak economic development, the uncertainties posed by Russia’s war of aggression and the situation in the Middle East, and global trade policy tensions will affect the operating environment of Aspocomp and its customers in the 2024 fiscal year. The company estimates that the demand in the Semiconductor segment will gradually recover starting from the first half of 2024, while at the same time unloading high inventory levels in various parts of the value chain. In order for investme
Nokia Corporation Interim Report for Q1 202418.4.2024 07:00:00 CEST | Press release
Nokia Corporation Interim report 18 April 2024 at 08:00 EEST Nokia Corporation Interim Report for Q12024 Strong cash flow and improving orders despite market weakness As expected, a slow start to 2024 with net sales declining 19% y-o-y in constant currency (-20% reported) in Q1.Environment still challenging but order trends continue to improve year-on-year, particularly in Network Infrastructure.Comparable gross margin in Q1 increased by 1 090bps y-o-y to 48.6% (reported increased 1 040bps to 47.9%). Strong contribution from Nokia Technologies which benefited from significant catch-up net sales, in addition to significant improvements in Mobile Networks due in part to regional and product mix. Q1 comparable operating margin increased 460bps y-o-y to 12.8% (reported up 130bps to 8.6%), as licensing catch-up net sales more than made up for low net sales coverage of operating expenses impacting other business groups.Q1 comparable diluted EPS of EUR 0.09; reported diluted EPS of EUR 0.08.Q